---
title: "Kezar Life Sciences’ Risk Disclosures Rely on Cross-References, Potentially Obscuring Full Risk Picture for Investors"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286043692.md"
description: "Kezar Life Sciences (KZR) has disclosed a new risk in its Regulation category, directing investors to Part I of its filings for a comprehensive discussion of potential risks. This reliance on cross-references may obscure the full risk picture for stakeholders. The average stock price target for KZR is $7.20, indicating a downside potential of -1.23%."
datetime: "2026-05-12T06:01:35.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286043692.md)
  - [en](https://longbridge.com/en/news/286043692.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286043692.md)
---

# Kezar Life Sciences’ Risk Disclosures Rely on Cross-References, Potentially Obscuring Full Risk Picture for Investors

Kezar Life Sciences (KZR) has disclosed a new risk, in the Regulation category.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

The disclosure directs investors to Part I of Kezar Life Sciences’ filings for a fuller discussion of potential risks and uncertainties beyond those summarized here. This reliance on cross-referenced sections may make it harder for stakeholders to quickly grasp the full scope of risks impacting Kezar’s operations and long-term prospects.

The average KZR stock price target is $7.20, implying -1.23% downside potential.

To learn more about Kezar Life Sciences’ risk factors, click here.

### Related Stocks

- [KZR.US](https://longbridge.com/en/quote/KZR.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)

## Related News & Research

- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [Genprex data shows gene therapy reverses hyperglycemia in T2D mice at ASGCT](https://longbridge.com/en/news/286414681.md)
- [Regenxbio's muscle disorder therapy meets main goal in late-stage study](https://longbridge.com/en/news/286406339.md)
- [US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug](https://longbridge.com/en/news/286394551.md)
- [Full Transcript: Cellectar Biosciences Q1 2026 Earnings Call](https://longbridge.com/en/news/286422585.md)